Recent studies reported that receptor tyrosine kinases (RTKs) such as c-Met and ALK contributed to PARPi resistance, and combined inhibition of these RTKs with PARPi induced synthetic lethality in breast cancer, liver cancer, pancreatic cancer, and ovarian cancer (28–33). The gene discussed is MET; the disease is breast carcinoma.